Vyome Holdings (HIND) FY2025 10-K Risk Factors: 53 New, 68 Dropped

What the changes say

Clinical-stage biopharmaceutical company focused on developing VT-1953 and VT-1908 following a corporate merger.
Faces substantial operating losses, lack of commercial revenue, and significant capital raising requirements.
Insider ownership is highly concentrated at over seventy-four percent.

What changed since the prior 10-K

New

NewRisks Related to Our Limited Operating History, Financial Condition and Capital Requirements
We have a limited operating history and have not taken a product through to commercialization
We have a limited operating history as a clinical-stage company and have not commercialized any products except for two in India.
NewRisks Related to Our Limited Operating History, Financial Condition and Capital Requirements
We have incurred losses since inception, and we expect to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability in the future. We have not generated any revenue from the Vyome Assets and may never generate revenue or become profitable
We have incurred losses since inception, generated no revenue from Vyome Assets, and may never achieve profitability.
NewRisks Related to Our Limited Operating History, Financial Condition and Capital Requirements
If we are unable to raise capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our development programs or future commercialization efforts
If unable to raise capital, we may have to delay or eliminate development programs for Vyome Assets.
NewRisks Related to Our Limited Operating History, Financial Condition and Capital Requirements
We may in the future license additional assets, which may require us to expend additional resources and raise additional capital
In-licensing additional assets will require extra resources and additional capital raising.
NewRisks Related to Our Limited Operating History, Financial Condition and Capital Requirements
We may not realize all of the anticipated benefits of the Merger
We may fail to realize the anticipated benefits and face integration difficulties or unknown liabilities from the Merger.
NewRisks Related to Our Product Development
We have never successfully completed the regulatory approval process for the Vyome Assets, and we may be unable to do so for any product candidates we acquire or develop
We have never completed the regulatory approval process for Vyome Assets and may fail to do so.
NewRisks Related to Our Product Development
We are substantially dependent on the success of VT-1953 and VT-1908, and our anticipated clinical trials of VT-1953 and VT-1908 may not be successful
Our success depends heavily on VT-1953, targeting a Phase 3 trial in early 2025, and VT-1908.
NewRisks Related to Our Product Development
We may find it difficult to enroll patients in our clinical trials for Vyome Assets. If we experience delays or difficulties in the enrollment of patients in clinical trials, our successful completion of clinical trials or receipt of marketing approvals could be delayed or prevented
We may experience clinical trial delays if we fail to enroll a sufficient number of patients.
NewRisks Related to Our Product Development
The results of preclinical testing and early clinical trials of the Vyome Assets may not be predictive of the success of our later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA, or other comparable foreign regulatory authorities
Preclinical and early clinical results of Vyome Assets may not predict success in later clinical trials required by regulators.
NewRisks Related to Our Product Development
Preclinical and clinical development involves a lengthy and expensive process with uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results
Developing VT-1953 for malodor in malignant fungating wounds requires lengthy trials and additional funding.
NewRisks Related to Our Product Development
Preliminary, interim data from our clinical trials that we announce or publish may change as more patient data become available and are subject to audit and verification procedures
Preliminary or interim clinical data we announce may change following more comprehensive reviews and audits.
NewRisks Related to Our Product Development
We may develop the Vyome Assets in combination with other therapies, which exposes us to additional risks related to other agents or active pharmaceutical or biological ingredients used in combination with the Vyome Assets
Developing Vyome Assets in combination with other therapies exposes us to regulatory or supply risks of those partner drugs.
NewRisks Related to Our Product Development
If the FDA or other regulatory authorities revoke their approval of these other drugs or revoke their approval of, or if safety, efficacy, manufacturing or supply issues arise with, the drugs we choose to evaluate in combination with any product candidate we develop, we may be unable to obtain approval
NewRisks Related to Our Product Development
VT-1953 and VT-1908 may have a safety profile that could prevent regulatory approval, marketing approval or market acceptance, or limit its commercial potential
NewRisks Related to Our Commercial Operations
We face substantial competition, which may result in others discovering, developing, licensing or commercializing products before or more successfully than we do
NewRisks Related to Our Commercial Operations
Public health crises such as pandemics or similar outbreaks have affected and could continue to seriously and adversely affect our preclinical studies and anticipated clinical trials, business, financial condition and results of operations
NewRisks Related to Our Commercial Operations
Our business, operations, financial position and clinical development plans and timelines could be materially adversely affected by the ongoing conflicts in various parts of the world
NewRisks Related to Our Business and Operations
We are dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining qualified personnel, including consultants, we may not be able to successfully implement our business strategy
NewRisks Related to Our Business and Operations
In order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience difficulties in managing this growth
NewRisks Related to Our Business and Operations
We generates all of our revenues from one customer, and loss of business from such customer could significantly harm our revenues and business
NewRisks Related to Our Business and Operations
We may, in the future, form or seek collaborations or strategic alliances or enter into licensing arrangements, and we may not realize the benefits of such collaborations, alliances or licensing arrangements
NewRisks Related to Our Business and Operations
The increasing use of social media platforms presents new risks and challenges
NewRisks Related to Our Business and Operations
Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
NewRisks Related to Our Intellectual Property
Our ability to protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage
NewRisks Related to Our Intellectual Property
We enjoy only limited geographical protection with respect to our licensed patents and may not be able to protect our intellectual property rights throughout the world
NewRisks Related to Our Intellectual Property
This list of territories has some notable omissions, particularly manufacturing territories such as China, India and Singapore for some of the Vyome Assets
NewRisks Related to Our Intellectual Property
Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these requirements
NewRisks Related to Our Intellectual Property
Issued patents covering one or more of our drug candidates could be found invalid or unenforceable
NewRisks Related to Our Intellectual Property
We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed confidential information of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors
NewRisks Related to Our Intellectual Property
Patent terms may be inadequate to protect our competitive position with respect to the Vyome Assets for an adequate amount of time
NewRisks Related to Our Intellectual Property
If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity for the Vyome Assets, our business may be materially harmed
NewRisks Related to Our Intellectual Property
It is possible that we will not obtain patent term extension under the Hatch-Waxman Act for a U.S. patent covering the Vyome Assets that we may identify even where that patent is eligible for patent term extension, or if we obtain such an extension, it may be for a shorter period than we had sought
NewRisks Related to Our Intellectual Property
Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect the Vyome Assets
NewRisks Related to Our Intellectual Property
We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market the Vyome Assets
NewRisks Related to Our Intellectual Property
We may be subject to claims challenging the inventorship of our patents and other intellectual property
NewRisks Related to Our Intellectual Property
We may be subject to patent infringement claims or may need to file claims to protect our intellectual property, which could result in substantial costs and liability and prevent us from commercializing the Vyome Assets
NewRisks Related to Our Intellectual Property
We may not be able to effectively secure first-tier technologies when competing against other companies or investors
NewRisks Related to Our Intellectual Property
Numerous factors may limit any potential competitive advantage provided by our intellectual property rights
NewRisks Related to Our Intellectual Property
If approved, the Vyome Assets that are regulated by FDA, EMA and other regulatory authorities may face competition from generics approved through an abbreviated regulatory pathway
NewRisks Related to Government Regulations and Other Legal Compliance Matters
We will be subject to extensive ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with the Vyome Assets
NewRisks Related to Government Regulations and Other Legal Compliance Matters
Due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, we may not be able to offer the Vyome Assets at competitive prices which would seriously harm our business
NewRisks Related to Government Regulations and Other Legal Compliance Matters
The FDA, EMA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses
NewRisks Related to Government Regulations and Other Legal Compliance Matters
Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
NewRisks Related to Government Regulations and Other Legal Compliance Matters
Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws in USA and India, which could expose us to penalties
NewRisks Related to Government Regulations and Other Legal Compliance Matters
The size of the potential market for the Vyome Assets is difficult to estimate and, if any of our assumptions are inaccurate, the actual markets for the Vyome Assets may be smaller than our estimates
NewRisks Related to Government Regulations and Other Legal Compliance Matters
Healthcare legislative reform discourse and potential or enacted measures may have a material adverse impact on our business and results of operations and legislative or political discussions surrounding the desire for and implementation of pricing reforms may adversely impact our business
NewRisks Related to Government Regulations and Other Legal Compliance Matters
If we fail to comply with environmental, health and safety laws and regulations in the USA, India or where we may have operations in future, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
NewRisks Related to Government Regulations and Other Legal Compliance Matters
We are subject to laws and regulations related to privacy, data protection, information security and consumer protection across different markets where we conduct our business. Our actual or perceived failure to comply with such obligations could harm our business
NewRisks Related to Government Regulations and Other Legal Compliance Matters
We do not have a compliance program in place consistent with Federal agencies’ guidance’s on corporate compliance programs
NewRisks Related to Government Regulations and Other Legal Compliance Matters
Our business is subject to certain laws and regulations in the jurisdictions in which it operates, many of which are currently evolving, and the risk of unfavorable interpretations or failure to comply with such laws and regulations could harm our business, financial condition and results of operations
NewRisks Related to Government Regulations and Other Legal Compliance Matters
Political changes in the Government of India could delay or affect the further liberalization of the Indian economy and materially and adversely affect economic conditions in India, generally, and our business, in particular
NewRisks Related to Government Regulations and Other Legal Compliance Matters
The government of India has traditionally exercised and continues to exercise influence over many aspects of the economy. Our business may be affected by interest rates, changes in policy, taxation, social and civil unrest and other political, economic or other developments in or affecting India
NewRisks Related to Government Regulations and Other Legal Compliance Matters
Our Indian subsidiary may not be in compliance with laws applicable to it, and it may face penalties and fines imposed by the Indian government

Dropped

DroppedRisks Related to Our Business and Industry
If we are unable to either substantially improve our operating results or obtain additional financing, we may be unable to continue as a going concern
Going concern risk due to insufficient cash and impact of GLP-1 drugs.
DroppedRisks Related to Our Business and Industry
If the warrants issued in our February 2025 offering are exercised by way of a “zero exercise price” alternative, especially after the reset date stockholders may suffer substantial dilution
Dilution risk from zero exercise price warrants issued in February 2025.
DroppedRisks Related to Our Business and Industry
We may be unable to attract and retain management and other personnel we need to succeed, particularly in light of the 2024 cost reduction plan
DroppedRisks Related to Our Business and Industry
We cannot assure you that we will ever generate substantial revenue or be profitable
Risk of losing key personnel following the 2024 cost reduction plan.
DroppedRisks Related to Our Business and Industry
We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives
Uncertainty of generating revenue for Lap-Band and Obalon systems.
DroppedRisks Related to Our Business and Industry
General economic and political conditions could have a material adverse effect on our business
DroppedRisks Related to Our Business and Industry
We face significant uncertainty in the industry due to government healthcare reform
Significant public company and Sarbanes-Oxley compliance costs.
DroppedRisks Related to Our Business and Industry
Failure to protect our information technology infrastructure against cyber-based attacks, network security breaches, service interruptions or data corruption could materially disrupt our operations and adversely affect our business
DroppedRisks Related to Our Business and Industry
We operate in a highly competitive industry that is subject to rapid change. If our competitors are able to develop and market products that are safer or more effective than our products, our commercial opportunities will be reduced or eliminated
General macroeconomic, interest rate, and healthcare political conditions.
DroppedRisks Related to Our Business and Industry
We face external competition from other technologies such as GLP-1’s, and alternative medical procedures and we may not be able to compete effectively
Impact of US healthcare reform initiatives like the Affordable Care Act.
DroppedRisks Related to Our Business and Industry
Adverse developments affecting the financial services industry could adversely affect our current and projected business operations and our financial condition and results of operations
DroppedRisks Related to the Pending Merger
Fluctuations in the market price of our common stock will affect the value of the Merger Consideration
IT infrastructure cyber attacks and service interruptions.
DroppedRisks Related to the Pending Merger
The Exchange Ratio in the Merger Agreement is subject to adjustment based on ReShape’s net cash as of a determination date prior to completion of the Merger, which could dilute further the ownership of either the ReShape or Vyome stockholders in the Combined Company
Obesity treatment market competition.
DroppedRisks Related to the Pending Merger
The ownership percentages of the ReShape and Vyome stockholders, respectively, that will result from the Exchange Ratio in the Merger Agreement are calculated prior to the completion of the Concurrent Financing, which could dilute further the ownership of the ReShape stockholders in the Combined Company
External competition from GLP-1 weight loss drugs.
DroppedRisks Related to the Pending Merger
The Merger may not be consummated unless important conditions are satisfied or waived and there can be no assurance that the Merger will be consummated
DroppedRisks Related to the Pending Merger
Although an application has been filed to list the ReShape Shares on The Nasdaq Capital Market, there can be no assurance that the common stock will be so listed or, if listed, that the Combined Company will be able to comply with the continued listing standards
Adverse financial impacts from Silicon Valley Bank closure.
DroppedRisks Related to the Pending Merger
The Merger Agreement contains provisions that could discourage a potential competing acquirer of either ReShape or Vyome
Stock price fluctuations affecting Merger consideration.
DroppedRisks Related to the Pending Merger
The pendency of the Merger could materially adversely affect the business, financial condition, results of operations or cash flows of ReShape or Vyome
DroppedRisks Related to the Pending Merger
ReShape directors and executive officers and Vyome directors and executive officers have interests in the Merger and Asset Sale that may be different from, or in addition to, the interests of ReShape stockholders and Vyome stockholders
DroppedRisks Related to the Pending Merger
With respect to the Asset Sale, certain of the executive officers of ReShape may become employees or consultants to Biorad after the closing of the Asset Sale, though no offers for such positions have been made and no terms of such positions have been discussed or negotiated
DroppedRisks Related to the Pending Merger
The members of the Vyome Board were aware of and considered these interests relating to Vyome, among other matters, in evaluating the Merger Agreement and the Merger, and in recommending that Vyome stockholders approve the Merger Agreement and the Merger
DroppedRisks Related to the Pending Merger
The opinion of ReShape’s financial advisor does not reflect changes in circumstances that may have occurred or that may occur between the signing of the Merger Agreement and the consummation of the Merger
DroppedRisks Related to the Pending Merger
Failure to consummate the Merger could negatively impact respective future operations and financial results of ReShape and Vyome and the future stock price of ReShape
DroppedRisks Related to the Pending Merger
The Merger may disrupt attention of ReShape management and Vyome management from ongoing business operations
DroppedRisks Related to the Pending Merger
The market price for ReShape Shares following completion of the Merger will continue to fluctuate and may be affected by factors different from those that historically have affected ReShape Shares
DroppedRisks Related to the Business of the Combined Company After the Merger
Combining the two companies may be more difficult, costly or time consuming than expected, and the Combined Company may not realize all of the anticipated benefits of the Merger
DroppedRisks Related to the Business of the Combined Company After the Merger
Both ReShape and Vyome have operated with a loss and negative cash flows for the entirety of their existence and it is expected the Combined Company will have to raise significant capital in the future that could be dilutive to stockholders of the Combined Company
DroppedRisks Related to the Business of the Combined Company After the Merger
You may not have the same benefits as an investor in an underwritten public offering
DroppedRisks Related to the Business of the Combined Company After the Merger
An active trading market for the Combined Company’s common stock may not develop and its stockholders may not be able to resell their shares of common stock for a profit, if at all
DroppedRisks Related to the Business of the Combined Company After the Merger
You may experience future dilution as a result of future equity offerings by the Combined Company
DroppedRisks Related to the Business of the Combined Company After the Merger
Post consummation of the Merger, the Combined Company may have outstanding warrants, which may cause dilution to its stockholders, have a material adverse impact on the market price of its common stock and make it more difficult for it to raise funds through future equity offerings
DroppedRisks Related to the Business of the Combined Company After the Merger
The Combined Company’s ability to use net operating losses (“NOL”) carryforwards may be limited
DroppedRisks Related to the Business of the Combined Company After the Merger
Any critical vendor bankruptcy or insolvency, or any breach or default by a critical vendor, or the loss of any significant vendor relationships, may have a material adverse impact on the Combined Company’s business
DroppedRisks Related to the Business of the Combined Company After the Merger
A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Combined Company’s annual or interim financial statements will not be prevented or detected and corrected on a timely basis
DroppedRisks Related to the Business of the Combined Company After the Merger
The Combined Company will incur increased costs as a result of operating as a public company, and its management will devote substantial time to related compliance initiatives
DroppedRisks Related to the Business of the Combined Company After the Merger
General economic and political conditions could have a material adverse effect on the Combined Company
DroppedRisks Related to the Business of the Combined Company After the Merger
If the Combined Company’s competitors are able to develop and market products that are safer or more effective than the Combined Company’s products, its commercial opportunities will be reduced or eliminated
DroppedRisks Related to the Business of the Combined Company After the Merger
The Combined Company may face significant uncertainty in the industry due to government healthcare reform
DroppedRisks Related to the Business of the Combined Company After the Merger
Failure to protect the Combined Company’s information technology infrastructure against cyber-based attacks, network security breaches, service interruptions or data corruption could materially disrupt its operations and adversely affect its business
DroppedRisks Related to the Business of the Combined Company After the Merger
The Combined Company may in the future become involved in lawsuits, to protect or enforce its intellectual property, which can be expensive and time consuming and could result in the diversion of significant resources
DroppedRisks Related to the Business of the Combined Company After the Merger
The Combined Company may lose important patents or patent rights if it does not timely pay required patent fees or annuities
DroppedRisks Related to the Business of the Combined Company After the Merger
Many of the Combined Company’s competitors may have significant resources and incentives to apply for and obtain intellectual property rights that could limit or prevent its ability to commercialize our current or future products in the United States or abroad
DroppedRisks Related to the Business of the Combined Company After the Merger
If the Combined Company is unable to protect the confidentiality of our proprietary information and know-how, the value of its technology and products could be adversely affected
DroppedRisks Related to the Business of the Combined Company After the Merger
Intellectual property litigation is a common tactic in the biotech industry to gain competitive advantage. If the Combined Company becomes subject to a lawsuit, it may be required to expend significant financial and other resources and our management’s attention may be diverted from its business
DroppedRisks Related to the Asset Sale
While the Asset Sale is pending, it creates unknown impacts on our future which could materially and adversely affect its business, financial condition and results of operations
DroppedRisks Related to the Asset Sale
The failure to consummate the Asset Sale may materially and adversely affect our business, financial condition and results of operations
DroppedRisks Related to the Asset Sale
The Merger may be consummated despite the Asset Sale not closing under certain circumstances
DroppedRisks Related to the Asset Sale
Our efforts to increase revenue from our Lap-Band System, Lap-Band 2.0 System, and commercialize our DBSN device and expanded line of bariatric surgical accessories, including ReShape Calibration Tubes, may not succeed or may encounter delays which could significantly harm our ability to generate revenue
DroppedRisks Related to the Asset Sale
We may not be able to obtain required regulatory approvals for our DBSN device in a cost-effective manner or at all, which could adversely affect our business and operating results
DroppedRisks Related to the Asset Sale
We depend on clinical investigators and clinical sites to enroll patients in our clinical trials, and on other third parties to manage the trials and to perform related data collection and analysis, and, as a result, we may face costs and delays that are outside of our control
DroppedRisks Related to the Asset Sale
Modifications to the Lap-Band and Lap-Band 2.0 system may require additional approval from regulatory authorities, which may not be obtained or may delay our commercialization efforts
DroppedRisks Related to the Asset Sale
If we or our suppliers fail to comply with ongoing regulatory requirements, or if we experience unanticipated product problems, our Lap-Band system could be subject to restrictions or withdrawal from the market
DroppedRisks Related to our Intellectual Property
If we are unable to obtain or maintain intellectual property rights relating to our technology and neuroblocking therapy, the commercial value of our technology and any future products will be adversely affected and our competitive position will be harmed
DroppedRisks Related to our Intellectual Property
We may lose important patents or patent rights if we do not timely pay required patent fees or annuities
DroppedRisks Related to our Intellectual Property
Many of our competitors have significant resources and incentives to apply for and obtain intellectual property rights that could limit or prevent our ability to commercialize our current or future products in the United States or abroad
DroppedRisks Related to our Intellectual Property
If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected
DroppedRisks Related to our Intellectual Property
Intellectual property litigation is a common tactic in the medical device industry to gain competitive advantage. If we become subject to a lawsuit, we may be required to expend significant financial and other resources and our management’s attention may be diverted from our business
DroppedRisks Related to our Intellectual Property
We may in the future become involved in lawsuits, to protect or enforce our intellectual property, which can be expensive and time consuming and could result in the diversion of significant resources
DroppedRisks Related to Equity Line of Credit
The sale or issuance of our common stock to Ascent may cause dilution and the sale of the shares of common stock acquired by Ascent, or the perception that such sales may occur, could cause the price of our common stock to fall
DroppedRisks Related to Equity Line of Credit
The purchase price for the shares that we may sell to Ascent under the Equity Purchase Agreement will fluctuate based on the price of our common stock. Depending on market liquidity at the time, sales of such shares may cause the trading price of our common stock to fall
DroppedRisks Related to Equity Line of Credit
Ascent will pay less than the then-prevailing market price for our common stock, which could cause the price of our common stock to decline
DroppedRisks Related to Equity Line of Credit
Our management will have broad discretion over the use of the net proceeds from our sale of shares of common stock to Ascent, and you may not agree with how we use the proceeds, and the proceeds may not be invested successfully
DroppedRisks Related to Equity Line of Credit
It is not possible to predict the actual number of shares we will sell under the Equity Purchase Agreement to Ascent, or the actual gross proceeds resulting from those sales
DroppedRisks Related to Equity Line of Credit
Investors who buy shares at different times will likely pay different prices
DroppedRisks Related to Equity Line of Credit
Our commitment to issue shares of common stock pursuant to the terms of the Equity Purchase Agreement could encourage short sales by third parties, which could contribute to the future decline of our stock price
DroppedRisks Relating to Ownership of our Common Stock
Sales of a substantial number of shares of our common stock in the public market by us or by our existing stockholders, or the perception that they may occur, could cause our stock price to decline
DroppedRisks Relating to Ownership of our Common Stock
Our organizational documents and Delaware law make a takeover of our company more difficult, which may prevent certain changes in control and limit the market price of our common stock
DroppedRisks Relating to Ownership of our Common Stock
We have not paid dividends in the past and do not expect to pay dividends in the future, and any return on investment may be limited to the value of our common stock

Reworded

93% rewrittenRisks Related to Our Business and Operations
We have identified material weaknesses in our internal control over financial reporting and any failure to maintain effective internal control over financial reporting, may have a material and adverse effect on our business, operating results, financial condition and prospects
Updated to reflect material weaknesses stemming from historical private company status and insufficient accounting resources as of December 31, 2025.
82% rewrittenRisks Related to Our Limited Operating History, Financial Condition and Capital Requirements
We have incurred substantial direct and indirect costs as a result of the Merger and expect to incur substantial direct and indirect costs following the Merger
Removed references to ReShape and updated merger cost language to focus solely on our ongoing expenses and potential stock price declines.
Was: ReShape and Vyome will incur substantial direct and indirect costs as a result of the Merger and the Combined Company will incur substantial direct and indirect costs following the Merger
81% rewrittenRisks Related to Ownership of Our Common Stock
Our principal shareholders, directors and executive officers own a significant percentage of our capital shares, and also have significant influence over our management
Updated insider voting ownership concentration to approximately 74.54% as of December 31, 2025, and added a reference to KKG Enterprises.
Was: The Combined Company’s principal shareholders, directors and executive officers will own a significant percentage of its capital shares, and also have significant influence over the Combined Company’s management
77% rewrittenRisks Related to Our Limited Operating History, Financial Condition and Capital Requirements
Our operating results may fluctuate significantly
Shifted operating result fluctuation references from the Combined Company to us, maintaining identical operational risk factors.
Was: The Combined Company’s operating results may fluctuate significantly
68% rewrittenRisks Related to Ownership of Our Common Stock
We do not expect to pay cash dividends in the foreseeable future. Any return on investment may be limited to the capital appreciation, if any, of shares of our common stock
Removed historical references to Vyome's pre-merger dividend status, applying cash dividend restrictions directly to our common stock.
Was: The Combined Company does not expect to pay cash dividends in the foreseeable future. Any return on investment may be limited to the capital appreciation, if any, of shares of common stock of the Combined Company
68% rewrittenRisks Related to Ownership of Our Common Stock
If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse opinion regarding our shares, our share price and trading volume could decline
Added a specific warning that loss of analyst coverage or failure to publish regularly could cause trading volume and share price declines.
Was: If securities or industry analysts do not publish research or reports about the Combined Company’s business, or if they issue an adverse opinion regarding its share, its share price and trading volume could decline
61% rewrittenRisks Related to Ownership of Our Common Stock
Raising additional capital may cause dilution to our existing shareholders, restrict our operations or require us to relinquish rights to the Vyome Assets or its product candidates
Added explicit warning that new equity incentive plans or increased share availability could cause additional dilution and stock price drops.
Was: Raising additional capital may cause dilution to the Combined Company’s existing shareholders, restrict its operations or require it to relinquish rights to Vyome’s assets or its product candidates
60% rewrittenRisks Related to Our Limited Operating History, Financial Condition and Capital Requirements
Previously, we recorded a non-cash indefinite-lived intangible and definite-lived assets impairment loss, which significantly impacted our results of operations, and we may be exposed to additional impairment losses that could be material
Updated historical asset impairment disclosures from the ReShape Vest to the Vyome Assets following previous trial stoppages.
54% rewrittenRisks Related to Our Limited Operating History, Financial Condition and Capital Requirements
Certain of our directors and executive officers also work with other companies and organizations and such other positions may create conflicts of interest in the future
Was: Certain of the Combined Company’s proposed directors and executive officers also work with other companies and organizations and such other positions may create conflicts of interest in the future
51% rewrittenRisks Related to Our Limited Operating History, Financial Condition and Capital Requirements
Our ability to use net operating losses (“NOL”) carryforwards may be limited
49% rewrittenRisks Related to Our Limited Operating History, Financial Condition and Capital Requirements
If the perceived benefits of the Merger do not meet the expectations of investors or securities analysists, the market price of our securities may decline
Was: If the perceived benefits of the Merger do not meet the expectations of investors or securities analysts, the market price of ReShape’s securities or, following the Merger, the Combined Company’s securities, may decline
43% rewrittenRisks Related to Ownership of Our Common Stock
Future sales of a substantial number of shares of our common stock may cause the price of our common stock to decline
Was: Future sales of a substantial number of shares of common stock of the Combined Company may cause the price of its common stock to decline
41% rewrittenRisks Related to Our Limited Operating History, Financial Condition and Capital Requirements
If financial institutions in which we hold funds for working capital and operating expenses were to fail, we cannot provide any assurances that such governmental agencies would take action to protect our uninsured deposits in a similar manner
Was: If financial institutions in which the Combined Company holds funds for working capital and operating expenses were to fail, there can be no assurance that such governmental agencies would take action to protect the Combined Company’s uninsured deposits in a similar manner
37% rewrittenRisks Related to Ownership of Our Common Stock
If we fail to meet all applicable Nasdaq Capital Market requirements, Nasdaq could delist our common stock, which could adversely affect the market liquidity of our common stock and the market price of our common stock could decrease
27% rewrittenRisks Related to Our Product Development
We face the risk of product liability claims that could be expensive, divert management’s attention and harm our reputation and business. We may not be able to obtain adequate product liability insurance
23% rewrittenRisks Related to Ownership of Our Common Stock
You may experience future dilution as a result of future equity offerings and exercise of put/call option under Option Agreements
Was: You may experience future dilution as a result of future equity offerings

All 72 risk factors

Headings as the filing states them, in filing order.

Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements

01We have a limited operating history and have not taken a product through to commercializationNew
02We have incurred losses since inception, and we expect to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability in the future. We have not generated any revenue from the Vyome Assets and may never generate revenue or become profitableNew
03Our ability to use net operating losses (“NOL”) carryforwards may be limited51% rewritten
04If financial institutions in which we hold funds for working capital and operating expenses were to fail, we cannot provide any assurances that such governmental agencies would take action to protect our uninsured deposits in a similar manner41% rewritten
05Previously, we recorded a non-cash indefinite-lived intangible and definite-lived assets impairment loss, which significantly impacted our results of operations, and we may be exposed to additional impairment losses that could be material60% rewritten
06If we are unable to raise capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our development programs or future commercialization effortsNew
07We may in the future license additional assets, which may require us to expend additional resources and raise additional capitalNew
08We may not realize all of the anticipated benefits of the MergerNew
09We have incurred substantial direct and indirect costs as a result of the Merger and expect to incur substantial direct and indirect costs following the Merger82% rewritten
10If the perceived benefits of the Merger do not meet the expectations of investors or securities analysists, the market price of our securities may decline49% rewritten
11Our operating results may fluctuate significantly77% rewritten
12Certain of our directors and executive officers also work with other companies and organizations and such other positions may create conflicts of interest in the future54% rewritten

Risks Related to Our Product Development

13We have never successfully completed the regulatory approval process for the Vyome Assets, and we may be unable to do so for any product candidates we acquire or developNew
14We are substantially dependent on the success of VT-1953 and VT-1908, and our anticipated clinical trials of VT-1953 and VT-1908 may not be successfulNew
15We may find it difficult to enroll patients in our clinical trials for Vyome Assets. If we experience delays or difficulties in the enrollment of patients in clinical trials, our successful completion of clinical trials or receipt of marketing approvals could be delayed or preventedNew
16The results of preclinical testing and early clinical trials of the Vyome Assets may not be predictive of the success of our later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA, or other comparable foreign regulatory authoritiesNew
17Preclinical and clinical development involves a lengthy and expensive process with uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial resultsNew
18Preliminary, interim data from our clinical trials that we announce or publish may change as more patient data become available and are subject to audit and verification proceduresNew
19We may develop the Vyome Assets in combination with other therapies, which exposes us to additional risks related to other agents or active pharmaceutical or biological ingredients used in combination with the Vyome AssetsNew
20If the FDA or other regulatory authorities revoke their approval of these other drugs or revoke their approval of, or if safety, efficacy, manufacturing or supply issues arise with, the drugs we choose to evaluate in combination with any product candidate we develop, we may be unable to obtain approvalNew
21VT-1953 and VT-1908 may have a safety profile that could prevent regulatory approval, marketing approval or market acceptance, or limit its commercial potentialNew
22We face the risk of product liability claims that could be expensive, divert management’s attention and harm our reputation and business. We may not be able to obtain adequate product liability insurance27% rewritten

Risks Related to Our Commercial Operations

23We face substantial competition, which may result in others discovering, developing, licensing or commercializing products before or more successfully than we doNew
24We have undertaken a cost reduction plan and reorganization, and may do so again in the future. The assumptions underlying these activities may prove to be inaccurate, or we may fail to achieve the expected benefits therefrom
25Public health crises such as pandemics or similar outbreaks have affected and could continue to seriously and adversely affect our preclinical studies and anticipated clinical trials, business, financial condition and results of operationsNew
26Our business, operations, financial position and clinical development plans and timelines could be materially adversely affected by the ongoing conflicts in various parts of the worldNew

Risks Related to Our Business and Operations

27We are dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining qualified personnel, including consultants, we may not be able to successfully implement our business strategyNew
28In order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience difficulties in managing this growthNew
29We generates all of our revenues from one customer, and loss of business from such customer could significantly harm our revenues and businessNew
30We may, in the future, form or seek collaborations or strategic alliances or enter into licensing arrangements, and we may not realize the benefits of such collaborations, alliances or licensing arrangementsNew
31The increasing use of social media platforms presents new risks and challengesNew
32Our disclosure controls and procedures may not prevent or detect all errors or acts of fraudNew
33We have identified material weaknesses in our internal control over financial reporting and any failure to maintain effective internal control over financial reporting, may have a material and adverse effect on our business, operating results, financial condition and prospects93% rewritten

Risks Related to Our Intellectual Property

34Our ability to protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantageNew
35We enjoy only limited geographical protection with respect to our licensed patents and may not be able to protect our intellectual property rights throughout the worldNew
36This list of territories has some notable omissions, particularly manufacturing territories such as China, India and Singapore for some of the Vyome AssetsNew
37Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these requirementsNew
38Issued patents covering one or more of our drug candidates could be found invalid or unenforceableNew
39We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed confidential information of our competitors or are in breach of non-competition or non-solicitation agreements with our competitorsNew
40Patent terms may be inadequate to protect our competitive position with respect to the Vyome Assets for an adequate amount of timeNew
41If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity for the Vyome Assets, our business may be materially harmedNew
42It is possible that we will not obtain patent term extension under the Hatch-Waxman Act for a U.S. patent covering the Vyome Assets that we may identify even where that patent is eligible for patent term extension, or if we obtain such an extension, it may be for a shorter period than we had soughtNew
43Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect the Vyome AssetsNew
44We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market the Vyome AssetsNew
45We may be subject to claims challenging the inventorship of our patents and other intellectual propertyNew
46We may be subject to patent infringement claims or may need to file claims to protect our intellectual property, which could result in substantial costs and liability and prevent us from commercializing the Vyome AssetsNew
47We may not be able to effectively secure first-tier technologies when competing against other companies or investorsNew
48Numerous factors may limit any potential competitive advantage provided by our intellectual property rightsNew
49If approved, the Vyome Assets that are regulated by FDA, EMA and other regulatory authorities may face competition from generics approved through an abbreviated regulatory pathwayNew

Risks Related to Government Regulations and Other Legal Compliance Matters

50We will be subject to extensive ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with the Vyome AssetsNew
51Due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, we may not be able to offer the Vyome Assets at competitive prices which would seriously harm our businessNew
52The FDA, EMA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label usesNew
53Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirementsNew
54Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws in USA and India, which could expose us to penaltiesNew
55The size of the potential market for the Vyome Assets is difficult to estimate and, if any of our assumptions are inaccurate, the actual markets for the Vyome Assets may be smaller than our estimatesNew
56Healthcare legislative reform discourse and potential or enacted measures may have a material adverse impact on our business and results of operations and legislative or political discussions surrounding the desire for and implementation of pricing reforms may adversely impact our businessNew
57Our operations, directly or indirectly through customers, may be subject to various state and federal fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute and federal False Claims Act. These laws may impact, among other things, our sales, marketing and education programs
58If we fail to comply with environmental, health and safety laws and regulations in the USA, India or where we may have operations in future, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our businessNew
59We are subject to laws and regulations related to privacy, data protection, information security and consumer protection across different markets where we conduct our business. Our actual or perceived failure to comply with such obligations could harm our businessNew
60We do not have a compliance program in place consistent with Federal agencies’ guidance’s on corporate compliance programsNew
61Our business is subject to certain laws and regulations in the jurisdictions in which it operates, many of which are currently evolving, and the risk of unfavorable interpretations or failure to comply with such laws and regulations could harm our business, financial condition and results of operationsNew
62Political changes in the Government of India could delay or affect the further liberalization of the Indian economy and materially and adversely affect economic conditions in India, generally, and our business, in particularNew
63The government of India has traditionally exercised and continues to exercise influence over many aspects of the economy. Our business may be affected by interest rates, changes in policy, taxation, social and civil unrest and other political, economic or other developments in or affecting IndiaNew
64Our Indian subsidiary may not be in compliance with laws applicable to it, and it may face penalties and fines imposed by the Indian governmentNew

Risks Related to Ownership of Our Common Stock

65The trading price of our common stock has been volatile and is likely to be volatile in the future
66We do not expect to pay cash dividends in the foreseeable future. Any return on investment may be limited to the capital appreciation, if any, of shares of our common stock68% rewritten
67Future sales of a substantial number of shares of our common stock may cause the price of our common stock to decline43% rewritten
68You may experience future dilution as a result of future equity offerings and exercise of put/call option under Option Agreements23% rewritten
69If we fail to meet all applicable Nasdaq Capital Market requirements, Nasdaq could delist our common stock, which could adversely affect the market liquidity of our common stock and the market price of our common stock could decrease37% rewritten
70If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse opinion regarding our shares, our share price and trading volume could decline68% rewritten
71Raising additional capital may cause dilution to our existing shareholders, restrict our operations or require us to relinquish rights to the Vyome Assets or its product candidates61% rewritten
72Our principal shareholders, directors and executive officers own a significant percentage of our capital shares, and also have significant influence over our management81% rewritten

Other Vyome Holdings 10-Ks

FY2024 10-K risk factors
87 risks
The company faces severe going concern risks, heavily dependent on closing its pending merger with Vyome. Operations and liquidity are severely strained by cash burn and GLP-1 weight loss drugs. Substantial dilution hangs over stockholders from pending warrant exercises and future capital raises.
Filed Apr 04, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.